GLP-1 Muscle Preservation
TL;DR
GLP-1 receptor agonists cause ~25–35% of weight lost to come from lean mass — a proportion similar to non-pharmacologic caloric restriction at comparable deficits. Resistance training ≥3×/week with 2.0–2.5 g protein/kg/day is the only evidence-supported preservation strategy. Bimagrumab (ActRII blockade) is the only pharmacologic with direct lean-gain evidence in humans (+3.6% at 48 weeks), but its obesity Phase 3 path is uncertain after a 2025 trial termination.
Why it matters for Vitals
Ben is on Retatrutide (GLP-1/GIP/GCGR triple agonist). The lean-mass fraction is real and affects:
- Body composition outcomes — net fat loss vs. net lean preservation is the difference between recomposition and just weight loss
- HRV interpretation — sustained nocturnal HRV suppression during GLP-1 therapy may signal catabolic stress, not just training load
- Wearable body composition — consumer BIA devices overestimate FFM by 3–8 kg vs. DEXA; scale weight alone is misleading during Retatrutide therapy
- Kidney function monitoring — creatinine becomes unreliable as eGFR proxy when muscle mass is changing rapidly; cystatin C is required
- Functional capacity — grip strength and neuromuscular performance are more relevant than scale weight for tracking adequacy of preservation efforts
Key facts
Lean mass fraction by agent
| Agent | Mechanism | Lean Mass Fraction | Evidence Grade | Method | Source |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg | GLP-1 | ~25–35% of weight lost as LM | A | DXA substudy (STEP 1, n~100) | PMID: 34030700 |
| Tirzepatide 10–15 mg | GLP-1 + GIP | ~33–39% of weight lost as LM | B | Bioimpedance (SURPASS-2); cross-trial | PMID: 34540099 |
| Retatrutide 4–12 mg | GLP-1 + GIP + glucagon | ~33–38% of weight lost as LM | B | DXA (Phase 2, limited data) | PMID: 37294850 |
| CagriSema 2.4/2.4 mg | GLP-1 + amylin | Numerically better FFM preservation vs semaglutide alone; exact % not primary endpoint | Supported | REDEFINE-1 Phase 3 body composition substudy | PMID: 40544433 |
| MariTide | GLP-1 + GIP antagonist | Muscle effect completely unknown | Gap | No body composition data published | PMID: 40549887 |
| Orforglipron | Oral GLP-1 | No body composition data; assume similar to other GLP-1s | Gap | ATTAIN program; no DXA substudy | — |
| Bimagrumab 30 mg/kg + semaglutide 2.4 mg | GLP-1 + ActRII blockade | Lean mass preserved/increased; only 7.3% of total weight lost as lean (vs 28.9% semaglutide alone) | Phase 2 RCT | BELIEVE trial, n=507, 48 wk | PMID: 41772149 |
GLP-1 FFM Systematic Review ACP 2026 — April 2026 ACP presentation: median 34.9% of GLP-1 weight loss is FFM (IQR 19–48.2%); 68% of 36 RCTs exceeded the ~25% caloric restriction benchmark. ACP 2026 / PMID 39481534.
Caveat: No head-to-head comparison at equivalent deficit, duration, and population. The glucagon component in retatrutide is theoretically the most catabolic but clinically unquantified.
Older and additional facts
- Lean fraction of weight lost: ~25–35% across GLP-1 agents; range 15–40% depending on population, dose, baseline composition, and co-interventions
- Semaglutide 2.4 mg: ~35% lean fraction (highest in meta-analyses) [Supported]
- Tirzepatide: ~25% lean fraction (consistent across subgroups) [Supported]
- Retatrutide (GLP-1/GIP/GCGR): lean fraction expected similar to other obesity treatments; GCGR cross-activation may amplify catabolism, not reduce it [Supported — inferred]
- Resistance training + lifestyle: 17.5% lean fraction (vs. 26.2% lifestyle alone or pharmacotherapy alone) [Supported — meta-analysis]
- Orforglipron: no body composition data published; lean mass fraction unknown; assume similar to other GLP-1s (~25–35% of weight as lean) [Gap]. See Orforglipron hub note.
- Bimagrumab + semaglutide 2.4 mg: −17.8 kg at 48 weeks vs. −9.3 kg bimagrumab alone, −14.2 kg semaglutide alone; +3.6% lean mass at 48 weeks (bimagrumab alone). Full data: Bimagrumab Semaglutide Combo Obesity [Phase 2 evidence]
- Functional outcomes: Handgrip strength +4.5 kg at 12 months on semaglutide 2.4 mg; sarcopenic obesity prevalence fell from 49% to 33% — muscle function often improves despite lean mass loss
- Omega-3 supplementation: no effect on muscle protein synthesis during caloric restriction (SMD 0.03, 95% CI −0.35 to 0.40) [Not supported]
- BCAA supplementation: identical lean mass loss vs. control during caloric restriction [Not supported]
- GHK-Cu, BPC-157, TB-500: zero published human RCTs for muscle-specific anabolic effects [Gap]
Mechanism summary
GLP-1 receptor agonism drives weight loss primarily via hypothalamic appetite suppression (GLP-1R), subcutaneous adipocyte lipid buffering (GIPR), and hepatic lipolysis + thermogenesis (GCGR). The GCGR component is the anti-plateau axis — it raises REE to prevent adaptive metabolic slowdown.
The resulting caloric deficit (~500–1000 kcal/day) creates a muscle-catabolic environment:
- AMPK activation — cellular energy sensor rises; inhibits mTORC1; promotes catabolism
- mTORC1 suppression — reduced muscle protein synthesis; reduced ribosomal biogenesis
- Insulin/IGF-1 suppression — reduced anabolic signaling
- Myostatin/ActRII axis — Smad2/3 signaling may increase with negative energy balance, further inhibiting mTORC1
The lean mass loss is proportional to the caloric deficit — it is not a unique GLP-1毒性. It mirrors what non-pharmacologic caloric restriction produces at similar deficits.
See mTOR AMPK Muscle Catabolism and ActRII Myostatin Pathway for the two mechanism notes.
What the current evidence suggests
| Claim | Evidence level | Verdict |
|---|---|---|
| GLP-1s cause proportional lean loss to caloric restriction | Strong — lean fraction mirrors non-pharmacologic restriction | Confirmed |
| Resistance training reduces lean fraction during GLP-1 therapy | Moderate — meta-analysis, limited head-to-head GLP-1+RT RCTs | Supported |
| Bimagrumab produces lean mass gain in humans | Moderate — Phase 2 RCT only; obesity Phase 3 path uncertain | Supported (limited) |
| Omega-3s preserve muscle during caloric restriction | Strong null — meta-analysis 8 RCTs | Not supported |
| BCAAs preserve muscle during caloric restriction | Moderate null — RCT | Not supported |
| GHK-Cu, BPC-157, TB-500 preserve muscle in humans | No published human RCTs | Gap |
Likely wearable / Vitals relevance
| Signal | Expected direction | Confidence | Notes |
|---|---|---|---|
| DEXA lean mass | Declining during active GLP-1 therapy without intervention | High | LSC 2–5.9% at 3 months; need 1.5–2 kg absolute change to exceed LSC |
| Grip strength | May improve despite lean mass loss (functional adaptation) | Moderate | Better proxy than scale weight; stronger correlation in males |
| Nocturnal HRV | Weight loss generally improves HRV; sustained suppression may signal catabolic overreaching | Low-moderate | Confounded by illness, alcohol, travel; needs trend not single day |
| Scale weight | Declining — misleading without body composition context | N/A | BIA devices add 3–8 kg FFM overestimate vs. DEXA |
| Creatinine | Falsely declining with muscle mass loss | Confound | Use cystatin C for kidney function monitoring |
| Resting HR | GLP-1 agents can raise RHR +5–10 bpm (Retatrutide dysesthesia signal) | Moderate | Separate from weight-loss HR reduction |
Risks and uncertainty
Populations most vulnerable
- Older adults ≥65 — accelerated sarcopenia risk; weight cycling post-cessation worsens body composition
- Sarcopenic obesity — least lean reserve to lose
- CKD, liver disease, IBD — impaired protein metabolism
- Without dietitian support — nutritional deficiencies diagnosed in 22.4% within 12 months of GLP-1 initiation
Creatinine artifact
Creatinine derives from the muscle creatine pool. As lean mass falls, serum creatinine falls — this can mask true kidney function decline by 12–16 mL/min/1.73m² over 15 years of muscle loss. Use cystatin C for monitoring during active GLP-1 therapy.
SGLT2 inhibitor interaction
SGLT2i + GLP-1 RA: OR 2.89 for falls vs. neither drug (vs. OR 1.80 for SGLT2i alone). Likely mediated by additive lean mass loss. Increased fall vigilance warranted.
Bimagrumab clinical path
Lilly terminated one Phase 2 obesity trial in September 2025. A remaining Phase 2 (NCT06643728) has results expected ~April 2026. FDA has signaled muscle composition alone may not be sufficient for approval — incremental weight loss over GLP-1 monotherapy is the likely bar.
Evidence gaps
- Zero of 36 RCTs measured physical function as a primary endpoint — no grip strength, no SPPB, no falls data as primary endpoints. Clinical significance of FFM loss is NOT established. ACP 2026 / PMID 39481534.
- No direct RCT evidence for protein dose-response during GLP-1-induced caloric deficit
- No long-term (>2 year) data on muscle function outcomes (strength, mobility, falls, fractures)
- Older adults (>65) with obesity during GLP-1 therapy severely underrepresented
- GHK-Cu, BPC-157, TB-500: no published human muscle protein synthesis data at therapeutic doses
- MariTide body composition completely unknown (GIP receptor antagonism — could worsen muscle partitioning)
- FFM recovery after GLP-1 discontinuation unstudied
⚠️ Evidence Extrapolation Flag
All protein intake recommendations in this note — including g/kg targets, supplement guidance, and protocol thresholds — are extrapolated from non-GLP-1 caloric restriction, athletic deficit, and older-adult anabolic resistance literature.
No RCT has tested different protein intake levels as an explicit intervention arm during any GLP-1 agonist treatment. The specific protein dose-response curve for muscle protein synthesis (MPS) during GLP-1-induced caloric deficit has not been established. Treat all g/kg targets as working approximations pending GLP-1-specific RCT data.
Protein Intake: Evidence and Uncertainty
| Evidence Base | Protein Recommendation | Grade | Confidence | Notes |
|---|---|---|---|---|
| Athletic deficit (Morton et al. 2018 meta-analysis) | 1.6–2.4 g/kg/day for LM retention | A | High | Not GLP-1-specific |
| Older adults ≥65, anabolic resistance | 2.0–2.4 g/kg/day | A | High | Not GLP-1-specific |
| GLP-1-specific RCT | NOT ESTABLISHED | — | Gap | Most critical evidence gap in field |
| Retatrutide + glucagon component | Potentially higher than above | — | Theoretical | Biologically plausible; clinically unquantified |
Working recommendation range (extrapolated, not GLP-1-proven):
- Adults: 1.8–2.2 g/kg actual body weight/day
- Older adults ≥65: 2.0–2.4 g/kg actual body weight/day
Protein supplement guidance
| Supplement | Leucine Content | Digestion Speed | GI Tolerability | Verdict |
|---|---|---|---|---|
| Whey protein isolate/concentrate | ~2.5–3 g leucine per 25 g serving | Fast | Moderate — liquid form better tolerated during GLP-1 GI peaks | Preferred per serving for MPS activation |
| Casein | ~2.2–2.5 g leucine per 30 g serving | Slow | Moderate | Secondary to total intake in GLP-1 context; modest overnight MPS advantage |
| Plant proteins (pea, soy, rice) | Lower leucine; ~1.5–2 g per 25 g serving | Variable | Better tolerated GI | Require larger total doses to reach MPS threshold; acceptable alternative |
GI tolerability note: Liquid protein supplements are better tolerated on GLP-1 GI peak days (2–5 days post-dose) than solid food. They may lack satiety signaling and can contribute to between-dose caloric grazing if not accounted for in logging.
Do not use BCAAs, HMB, or creatine for muscle preservation in the GLP-1 context — no published RCT evidence supports any of these specifically during GLP-1 therapy.
Best stack context
During active Retatrutide therapy:
- Resistance training ≥3 sessions/week (major muscle groups; progressive overload) — the anchor intervention
- Protein intake 2.0–2.5 g/kg/day (split across meals; 30–40 g per meal) — necessary but not sufficient alone
- GHK-Cu — skin laxity prevention; zero muscle-specific evidence but reasonable for ECM remodeling context
- BPC-157 — tissue repair context only; no muscle preservation evidence
- TB-500 — research-only; no human muscle preservation data
- Bimagrumab — only pharmacologic with lean gain data; clinical path uncertain; consider after Phase 2 results (~April 2026)
Do not stack GHK-Cu + BPC-157 + TB-500 on the premise of muscle preservation — no human RCT evidence supports any of them for this purpose.
What stays inside this hub
- Specific formulation logistics for compounded peptides
- Proprietary company development details
- The full 20+ source citation list (source doc has this; key PMIDs are embedded in key facts)
- The full protein intake monograph content (batch-41-2026-04-20/protein-intake-lean-mass-retention-glp1-glucagon-agonists.md) has been selectively integrated into this note — key evidence tables, supplement guidance, and Vitals protocols are here; granular mechanistic text and claims registry remain in the source monograph
Related notes
Mechanism notes
- mTOR AMPK Muscle Catabolism — the central signaling pathway governing muscle protein synthesis vs. breakdown during caloric deficit
- ActRII Myostatin Pathway — the myostatin/activin axis and ActRII blockade; bimagrumab mechanism
- GLP-1 GIP Glucagon — the receptor pharmacology of incretin/GCGR agonists
- Autophagy — cellular quality control upregulated during caloric deficit
- Mitophagy — mitochondrial quality control during metabolic stress
Substance notes
- Retatrutide — Ben’s primary GLP-1 agent; lean mass impact expected
- GHK-Cu — Ben’s protocol; no muscle preservation evidence but used for ECM/skin context
- BPC-157 — Ben’s protocol; no muscle preservation evidence
- TB-500 — Ben’s protocol; no human muscle preservation data
- Berberine — AMPK activator; GLP-1 secretagogue; additive glucose-lowering risk
- SGLT2 Inhibitors — fall risk amplifier when combined with GLP-1 therapy
Biometrics / Protocol notes
- HRV — wearable recovery signal; catabolic stress detection
- HRV Guided Training — HRV-based training decisions
- Resistance Training for Longevity — the evidence-backed anchor for muscle preservation
- Blood Biomarker Optimization — IGF-1, cystatin C, nutritional panel tracking
- Protein Intake GLP-1 Glucagon — protein intake protocol for GLP-1 agonist users (1.8–2.2 g/kg), DXA monitoring, BUN/urea compliance check; Batch 41 canonical source
MOC
- Peptides MOC — Retatrutide, GHK-Cu, BPC-157, TB-500 all listed here
- Vitals Knowledge Map — top-level index
Vitals Protocols
1. DXA Body Composition Monitoring Protocol
Trigger: Patient initiating or currently on any GLP-1 agonist therapy.
| Timepoint | Action |
|---|---|
| Baseline (week 0–1) | Schedule DXA scan before or during week 1 of therapy |
| Every 12 weeks | Follow-up DXA; minimum 2 follow-up scans before issuing body composition guidance |
| Ongoing | Track at minimum every 6 months during active therapy |
Estimated lean mass risk by compound:
- Semaglutide: ~40% of weight lost as lean mass
- Tirzepatide: ~25–35% lean mass proportion
- Retatrutide: ~30–35% lean mass proportion (additional glucagon risk theoretical)
⚠️ All protein g/kg targets used in protocol interpretation are extrapolated from non-GLP-1 evidence. Human sign-off required before issuing patient-specific targets.
2. BUN Compliance Check (Protein Intake Proxy)
Purpose: BUN (blood urea nitrogen) as a rough proxy for nitrogen flux and protein intake compliance. Elevated BUN during high-protein diet indicates protein intake is being metabolized — not necessarily directed to MPS, but confirms intake.
| BUN Range | Interpretation |
|---|---|
| 7–20 mg/dL | Normal / low protein intake |
| 25–35 mg/dL | Consistent with high-protein diet (benign) |
| >40 mg/dL | Warrants clinical review for renal concern |
Compliance check: Estimated protein intake (g/day) ≈ (BUN − 7) × 0.5 × weight (kg). Compare against target. If estimated intake ≥80% of target → compliant.
⚠️ Food logging (Cronometer) + 24-hour urine collection preferred over BUN alone. BUN is approximate; hydration status, liver function, and catabolic states also affect BUN.
3. Grip Strength Tracking Protocol
Purpose: Functional proxy for lean mass integrity. Declining grip strength despite weight loss is a red flag for inadequate lean mass preservation.
Frequency: Monthly hand dynamometer measurement.
| Age/Sex | Reference Grip Strength (kg) | Concern Threshold |
|---|---|---|
| Male 30s | 45 | <36 kg |
| Male 40s | 43 | <34 kg |
| Male 50s | 40 | <32 kg |
| Male 60s | 36 | <29 kg |
| Male 70s | 30 | <24 kg |
| Female 30s | 28 | <22 kg |
| Female 40s | 27 | <22 kg |
| Female 50s | 25 | <20 kg |
| Female 60s | 22 | <18 kg |
| Female 70s | 18 | <14 kg |
⚠️ Grip strength reference norms (PMID: 31577396). Below 80% of age/sex reference = possible sarcopenia flag. Grip strength may improve despite lean mass loss (functional adaptation); use DXA as confirmatory test.
Sources (key PMIDs embedded in key facts; full list in source doc)
PMID: 41877354 · 39719170 · 38629387 · 39996356 · 33439265 · 41772149 · 38777807 · 33537760 · 38898741 · 40097434 · 39985672 · 24092765 · 40584822 · 41068996 · 41850248 · 41579235 · 40609566 · 40819408